STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a
Bristol Myers Squibb will buy CNS drugmaker Karuna Therapeutics for cash in a deal valued at $14 billion, the companies announced Friday morning. The move
By Company Name No Filter Selected Bristol-Myers Squibb (370) Merck (239) AstraZeneca (190) Novartis (162) AbbVie (145) BeiGene (136) Pfizer (123) F. Hoffmann-La Roche (122)
By Company Name No Filter Selected Bristol-Myers Squibb (370) Merck (239) AstraZeneca (190) Novartis (162) AbbVie (145) BeiGene (136) Pfizer (123) F. Hoffmann-La Roche (122)
Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on Thursday.
A MedPage Today Clinical Challenges series on breast cancer reviewed locoregional therapy for older patients, the management of invasive lobular cancer (ILC), and the treatment
The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases
Claire Panosian Dunavan is a professor of medicine and infectious diseases at the David Geffen School of Medicine at UCLA and a past-president of the
The FDA continues its investigation into counterfeit semaglutide (Ozempic) products — which may still be available for purchase — and has already seized thousands of
In older overweight individuals with rheumatoid arthritis (RA), a composite of metabolic biomarkers as well as disease activity measures improved substantially with a professionally directed